Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Cindy Spittle"'
Autor:
Jessica Kristof, Kellen Sakrison, Xiaoping Jin, Kenji Nakamaru, Matthias Schneider, Robert A Beckman, Daniel Freeman, Cindy Spittle, Wenqin Feng
Publikováno v:
Biomarker Insights, Vol 12 (2017)
In preclinical studies, heregulin ( HRG ) expression was shown to be the most relevant predictive biomarker for response to patritumab, a fully human anti–epidermal growth factor receptor 3 monoclonal antibody. In support of a phase 2 study of erlo
Externí odkaz:
https://doaj.org/article/d370f46b4155425ea8597a761feb80d1
Autor:
Gregory Chang, Nathaniel H. Fleming, Yongzhao Shao, Cindy Spittle, Farbod Darvishian, Russell S. Berman, Iman Osman, Mahrukh M. Syeda, George Karlin-Neumann, Anna C. Pavlick, Richard L. Shapiro, Jyothirmayee S. Tadepalli, Shria Blake, Jennifer M. Wiggins, Broderick Corless, David Polsky
Publikováno v:
The Journal of investigative dermatology. 140(8)
Mutational heterogeneity can contribute to therapeutic resistance in solid cancers. In melanoma, the frequencies of intertumoral and intratumoral heterogeneity are controversial. We examined mutational heterogeneity within individual patients with me
Autor:
Mahrukh M, Syeda, Jennifer M, Wiggins, Broderick, Corless, Cindy, Spittle, George, Karlin-Neumann, David, Polsky
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2055
The detection of cell-free, circulating tumor DNA (ctDNA) in the blood of patients with solid tumors is often referred to as "liquid biopsy." ctDNA is particularly attractive as a candidate biomarker in the blood. It is relatively stable after blood
Autor:
Broderick Corless, Mahrukh M. Syeda, David Polsky, Cindy Spittle, Jennifer M. Wiggins, George Karlin-Neumann
Publikováno v:
Biomarkers for Immunotherapy of Cancer ISBN: 9781493997725
The detection of cell-free, circulating tumor DNA (ctDNA) in the blood of patients with solid tumors is often referred to as "liquid biopsy." ctDNA is particularly attractive as a candidate biomarker in the blood. It is relatively stable after blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e580935cc149d7efbab0c607074f56ec
https://doi.org/10.1007/978-1-4939-9773-2_7
https://doi.org/10.1007/978-1-4939-9773-2_7
Publikováno v:
Cancer Research. 80:896-896
Introduction: Chimeric antigen receptor T (CAR T) cells are an important emerging therapy for hematologic malignancies and are currently being investigated for other cancer types as well. CAR-T cells require a retrovirus or lentivirus to introduce th
Autor:
David Polsky, Iman Osman, Mahrukh M. Syeda, Cindy Spittle, Broderick Corless, George Karlin-Neumann
Publikováno v:
Clinical Cancer Research. 26:A66-A66
Introduction: Serial monitoring of sensitive and specific blood-based biomarkers of disease burden in cancer patients could enable clinicians to adjust treatments at the earliest signs of disease progression when the likelihood of improved outcomes i
Autor:
Dawne N. Shelton, Jyothirmayee S. Tadepalli, Manohar R. Furtado, Yilong Zhang, Anna C. Pavlick, Sarah A. Weiss, Eric Robinson, Iman Osman, George Karlin-Neumann, David Polsky, Yongzhao Shao, Cindy Spittle, Gregory Chang
Publikováno v:
Molecular Oncology. 10:157-165
Melanoma lacks a clinically useful blood-based biomarker of disease activity to help guide patient management. To determine whether measurements of circulating, cell-free, tumor-associated BRAF(mutant) and NRAS(mutant) DNA (ctDNA) have a higher sensi
Autor:
Richard L. Shapiro, George Karlin-Neumann, Gregory Chang, Cindy Spittle, Farbod Darvishian, Iman Osman, Broderick Corless, Anna C. Pavlick, Nathaniel H. Fleming, Russell S. Berman, David Polsky
Publikováno v:
Cancer Research. 79:4704-4704
Purpose: The mutational spectra of melanoma has been well characterized; however, the presence of distinct subclones among multiple tumors from a given patient has been less well described. As mutational heterogeneity has been associated with decreas
Autor:
David Smith, Kevin Hawkins, Kristy Drafahl, Cindy Spittle, Chad Galderisi, Cristen Graham, Shouryadeep Srivastava, Scott Verrow, Victor M. Rivera, Christine Glynn
Publikováno v:
Blood. 132:1558-1558
In Ph+ ALL, the absence of detectable disease has shown prognostic value for a reduced risk of relapse and improved survival. However, as the level of undetectable disease is determined by the lower limit of detection of the test in use, standardizat
Autor:
Xiaodong Wang, Weihua Liu, Zhenyu Yan, Cindy Spittle, Chad Galderisi, Jin Li, Peng Fang, Scott Glynn, Jennifer Biroschak
Publikováno v:
Cancer Research. 78:4522-4522
FLT3 ITD, a prognostic marker and drug target, is present in ~19% of AML patients. FLT3 ITD is a tandem repeat of the entire or partial exon 13-15 region. FLT3 ITDs range in size from 3bp to above 300bp and impact RTK signaling. Recent publications h